<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18246" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Bevacizumab</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gerriets</surname>
            <given-names>Valerie</given-names>
          </name>
          <aff>California Northstate University College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kasi</surname>
            <given-names>Anup</given-names>
          </name>
          <aff>University of Kansas</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Valerie Gerriets declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anup Kasi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18246.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor A (VEGF-A). It is used to treat several different cancers (cervical cancer, metastatic colorectal cancer, glioblastoma, non-squamous non-small cell lung cancer, ovarian, fallopian tube, primary peritoneal cancer, metastatic renal cell carcinoma, and hepatocellular carcinoma ). The administration of bevacizumab inhibits microvascular growth and angiogenesis and is used in cancer treatment to inhibit malignant cell growth and blood vessel formation. It is usually administered in combination with other chemotherapy agents. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team in the treatment of patients with bevacizumab.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the approved indications for bevacizumab.</p></list-item><list-item><p>Summarize the mechanism of action of bevacizumab.</p></list-item><list-item><p>Review the potential adverse events of bevacizumab.</p></list-item><list-item><p>Outline interprofessional team strategies for improving care coordination and communication to advance bevacizumab and improve outcomes in cancer treatment.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18246&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18246">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18246.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor A (VEGF-A) and is used to treat the below conditions. Its use is typically in combination with other chemotherapy agents.<xref ref-type="bibr" rid="article-18246.r1">[1]</xref><xref ref-type="bibr" rid="article-18246.r2">[2]</xref><xref ref-type="bibr" rid="article-18246.r3">[3]</xref></p>
        <p>
<bold>FDA-approved Indications</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Cervical cancer: Bevacizumab has approval for treating recurrent, persistent, or metastatic cervical cancer in combination with paclitaxel and either cisplatin or topotecan.</p>
          </list-item>
          <list-item>
            <p>Metastatic colorectal cancer: Bevacizumab is a first-line or second-line therapy for metastatic colorectal cancer combined with fluorouracil (FU)-based chemotherapy regimens.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Glioblastoma: Bevacizumab has approval as a single agent in patients with progressive glioblastoma following previous therapy.</p>
          </list-item>
          <list-item>
            <p>Non-squamous non-small cell lung cancer (NSCLC): Bevacizumab is a first-line treatment combination with carboplatin and paclitaxel for recurrent, locally advanced, unresectable, or metastatic non-squamous non-small cell lung cancer.<xref ref-type="bibr" rid="article-18246.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Ovarian, fallopian tube, or primary peritoneal cancer: Bevacizumab has approved the treatment of platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with a carboplatin chemotherapy regimen or the treatment of platinum-resistant disease in combination with paclitaxel, doxorubicin, or topotecan.<xref ref-type="bibr" rid="article-18246.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Metastatic renal cell carcinoma: Bevacizumab has&#x000a0;received approval&#x000a0;to treat metastatic renal cell carcinoma in combination with interferon alfa.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hepatocellular carcinoma (HCC): Bevacizumab, in combination with atezolizumab, is indicated for treating unresectable metastatic hepatocellular carcinoma patients.<xref ref-type="bibr" rid="article-18246.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-label Indications</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Metastatic breast cancer<xref ref-type="bibr" rid="article-18246.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Endometrial cancer</p>
          </list-item>
          <list-item>
            <p>Angiosarcoma</p>
          </list-item>
          <list-item>
            <p>Gliomas</p>
          </list-item>
          <list-item>
            <p>Malignant pleural mesothelioma</p>
          </list-item>
          <list-item>
            <p>Medulloblastoma (pediatric)</p>
          </list-item>
          <list-item>
            <p>Diabetic macular edema</p>
          </list-item>
          <list-item>
            <p>Age-related macular degeneration</p>
          </list-item>
          <list-item>
            <p>Hemangiopericytoma and malignant solitary fibrous tumor</p>
          </list-item>
          <list-item>
            <p>Hereditary hemorrhagic telangiectasia<xref ref-type="bibr" rid="article-18246.r8">[8]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18246.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Bevacizumab is a recombinant humanized monoclonal antibody that binds to all known vascular endothelial growth factor A (VEGF-A) isoforms. It blocks the interaction between VEGF-A and the VEGF receptors (VEGFR), primarily VEGFR-1 (fit-1) and VEGFR-2 (KDRflk-1), on the surface of endothelial cells. It is 93% human and 7% murine in the protein sequence. The binding of VEGF-A to VEGFR-1 and VEGFR-2 leads to endothelial cell proliferation, the activation of survival pathways, and the formation of new blood vessels and angiogenesis. Therefore, the administration of bevacizumab inhibits microvascular growth and angiogenesis and is used in cancer treatment to inhibit malignant cell growth and blood vessel formation.<xref ref-type="bibr" rid="article-18246.r9">[9]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Absorption:&#x000a0;A&#x000a0;PK study&#x000a0;concluded bevacizumab follows linear pharmacokinetics and is expected to reach 90% of steady-state concentration by 84&#x000a0;days.<xref ref-type="bibr" rid="article-18246.r10">[10]</xref></p>
        <p>Distribution: The volume of distribution is 2.9 L. After correcting for body weight, males have a larger central volume of distribution (3.2 L vs. 2.7 L) than females.<xref ref-type="bibr" rid="article-18246.r11">[11]</xref></p>
        <p>Metabolism: The metabolism of bevacizumab is likely identical to endogenous antibodies like IgG, i.e., by proteolytic catabolism, involving non-specific elimination pathways and target-mediated elimination by VEGF-expressing cells. Hence it doesn't affect the activity of drug-metabolizing enzymes in the liver.<xref ref-type="bibr" rid="article-18246.r12">[12]</xref><xref ref-type="bibr" rid="article-18246.r13">[13]</xref></p>
        <p>Elimination:&#x000a0;The mean clearance is 0.23 L/day. After correcting for body weight, clearance is approximately 26% higher in men than in women. The estimated half-life is 20 days. The clearance of bevacizumab alters by body weight, sex, and tumor burden. Clearance&#x000a0;is reduced with&#x000a0;increased albumin and&#x000a0;reduced alkaline phosphatase.<xref ref-type="bibr" rid="article-18246.r10">[10]</xref><xref ref-type="bibr" rid="article-18246.r11">[11]</xref></p>
      </sec>
      <sec id="article-18246.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Bevacizumab administration is via intravenous (IV) infusion.&#x000a0;Bevacizumab comes in 100 mg and 400 mg solutions in 4 mL and 16 mL, respectively.<xref ref-type="bibr" rid="article-18246.r14">[14]</xref> The first infusion should be over 90 minutes and subsequent infusions over 60 minutes if the first infusion is well tolerated. Additional infusions can be given over 30 minutes if the patient tolerates the 60-minute infusion well. There are many different dosing regimens based on the type of cancer treated; most fall between 5 mg to 15 mg/kg body weight on a cyclical treatment schedule (14 or 21 days), also depending on the type of cancer being treated.<xref ref-type="bibr" rid="article-18246.r15">[15]</xref>&#x000a0;Bevacizumab&#x000a0;is also given off-label as an intravitreal injection for ophthalmic conditions such as&#x000a0;macular edema and age-related macular degeneration.<xref ref-type="bibr" rid="article-18246.r16">[16]</xref></p>
        <p>
<bold>Use in Specific Patient Populations</bold>
</p>
        <p><bold>Patients with Hepatic Impairment:</bold> No information about dose adjustment is provided in the manufacturer's labeling. Based on the literature review, no dose adjustment is likely needed in hepatic impairment.<xref ref-type="bibr" rid="article-18246.r17">[17]</xref></p>
        <p><bold>Patients with Renal Impairment: </bold>No dose adjustment is suggested for renal impairment. However, nephrotoxicity manifested by proteinuria and nephrotic syndrome has been reported in the literature.&#x000a0;Bevacizumab administration should be temporarily withheld&#x000a0;if 24-hour urine protein levels are &#x0003e;2 g, and&#x000a0;it should be resumed&#x000a0;when levels are &#x0003c;2 g. Treatment discontinuation is recommended in nephrotic syndrome.<xref ref-type="bibr" rid="article-18246.r18">[18]</xref></p>
        <p><bold>Pregnancy Considerations:</bold> Dysregulation of VEGF due to bevacizumab therapy is associated with preeclampsia. Case reports suggest that preeclampsia resolved on discontinuation of bevacizumab.<xref ref-type="bibr" rid="article-18246.r19">[19]</xref>&#x000a0;In addition,&#x000a0;VEGF plays a role in maintaining the corpus luteum and amniotic fluid regulation. Hence&#x000a0;clinicians should perform a&#x000a0;risk-benefit evaluation, and pregnant mothers should be informed regarding the risk of bevacizumab therapy during pregnancy.<xref ref-type="bibr" rid="article-18246.r20">[20]</xref>&#x000a0;</p>
        <p>Women of childbearing age should be&#x000a0;informed regarding the potential adverse effects of intravitreal bevacizumab on fetal health and should&#x000a0;be encouraged&#x000a0;to use&#x000a0;proper contraceptive methods&#x000a0;during treatment. Intravitreal bevacizumab should be avoided, particularly during the first trimester, as susceptibility to teratogens is maximum&#x000a0;during organogenesis (3&#x000a0;to 8 weeks postconception).<xref ref-type="bibr" rid="article-18246.r21">[21]</xref></p>
        <p><bold>Breastfeeding Considerations:&#x000a0;</bold>Bevacizumab has a high molecular weight, and&#x000a0;the&#x000a0;concentration&#x000a0;in milk is likely to be low. However, VEGF&#x000a0;is believed to assist in the maturation of the infant's gastrointestinal tract; hence use of VEGF inhibitors during breastfeeding is not advised. In addition, there is a lack of clinical data; hence&#x000a0;it is recommended that breastfeeding should be stopped during intravenous&#x000a0;bevacizumab treatment and for six months&#x000a0;after the last dose due to the possibility of serious drug adverse reactions in breastfed infants. Similarly, intravitreal bevacizumab has the longest half-life of the VEGF inhibitors used in eye disorders, and an alternate intravitreal agent(Aflibercept, ranibizumab) may be preferred.<xref ref-type="bibr" rid="article-18246.r22">[22]</xref></p>
      </sec>
      <sec id="article-18246.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The following adverse effects (AEs) were observed in greater than 10% of patients receiving bevacizumab, both as a single agent and in combination with other chemotherapy agents, including paclitaxel, carboplatin, interferon alfa, fluorouracil, and others<xref ref-type="bibr" rid="article-18246.r23">[23]</xref><xref ref-type="bibr" rid="article-18246.r24">[24]</xref>:</p>
        <p>
<bold>Cardiovascular</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension (19% to 42%), venous thromboembolism (secondary: 21%; with oral anticoagulants), peripheral edema (15%), hypotension (7% to 15%)</p>
          </list-item>
        </list>
        <p>
<bold>Central Nervous System</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Fatigue (33% to 82%), pain (8% to 62%), headache (22% to 49%), dizziness (13% to 26%), insomnia (21%), taste disorder (14% to 21%), peripheral sensory neuropathy (17% to 18%), anxiety (17%), myasthenia (13%)</p>
          </list-item>
        </list>
        <p>
<bold>Dermatology</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Alopecia (6% to 32%), exfoliative dermatitis (23%), palmar-plantar erythrodysesthesia (11%)</p>
          </list-item>
        </list>
        <p>
<bold>Endocrine</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hyperglycemia (26% to 31%), hypomagnesemia (24% to 27%), weight loss (15% to 21%), hyponatremia (17% to 19%), hypoalbuminemia (11% to 16%), hypocalcemia (12%)</p>
          </list-item>
        </list>
        <p>
<bold>Gastrointestinal</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nausea (72%), abdominal pain (33% to 61%), vomiting (33% to 52%), anorexia (35% to 43%), constipation (40%), diarrhea (21% to 39%), decreased appetite (34% to 35%), stomatitis (15% to 33%), gastrointestinal hemorrhage (19% to 24%), dyspepsia (17% to 24%), mucosal inflammation (13% to 15%)</p>
          </list-item>
        </list>
        <p>
<bold>Hematology</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Thrombocytopenia (5% to 58%),&#x000a0; leukopenia (grades 3/4: 37%), neutropenia (12%; grades &#x02265;3: 8% to 27%, grade 4: 27%), bruise (17%), lymphocytopenia (12%)</p>
          </list-item>
        </list>
        <p>
<bold>Musculoskeletal</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Arthralgia (28% to 45%), myalgia (19% to 29%), limb pain (25%), back pain (12% to 21%), dysarthria (8% to 14%)</p>
          </list-item>
        </list>
        <p>
<bold>Renal</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Increased serum creatinine (13% to 16%)</p>
          </list-item>
        </list>
        <p>
<bold>Respiratory</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Upper respiratory tract infection (40% to 47%), cough (26% to 30%), dyspnea (25% to 30%), allergic rhinitis (17%), oropharyngeal pain (16%), sinusitis (7% to 15%), nasal sign and symptoms (mucosal disorder: 14%)</p>
          </list-item>
        </list>
        <p>
<bold>Miscellaneous</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Infection (55%), urinary tract infection (22%), pelvic pain (14%)</p>
          </list-item>
        </list>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Gastrointestinal perforations: Gastrointestinal (GI) perforations, some fatal, have been seen in patients treated with bevacizumab. It should be discontinued in patients with GI perforations. Most cases occurred within 50 days of treatment initiation. In particular, GI perforations were observed in ovarian cancer patients.<xref ref-type="bibr" rid="article-18246.r25">[25]</xref>&#x000a0;The incidence of GI complications is highest in patients with cervical cancer.<xref ref-type="bibr" rid="article-18246.r26">[26]</xref><xref ref-type="bibr" rid="article-18246.r27">[27]</xref>&#x000a0;Discontinue bevacizumab in patients who develop gastrointestinal perforation and tracheoesophageal fistula.<xref ref-type="bibr" rid="article-18246.r28">[28]</xref><xref ref-type="bibr" rid="article-18246.r29">[29]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hemorrhage: Serious or fatal hemorrhage, including GI bleeding, central nervous system hemorrhage, vaginal bleeding, hemoptysis, and epistaxis, occur up to five times more frequently in patients receiving bevacizumab. These reports have primarily been in non-small cell lung cancer patients with squamous&#x000a0;cell&#x000a0;histology and a history of hemoptysis (grade &#x02265;2).<xref ref-type="bibr" rid="article-18246.r30">[30]</xref>&#x000a0;Intracranial hemorrhage has been observed in patients previously treated for glioblastoma. The&#x000a0;possible mechanism of bevacizumab included disruption of endothelial cell integrity in the tumor microvasculature. Concerns of life-threatening hemorrhage&#x000a0;are high, but&#x000a0;a retrospective review of 10,598 cancer patients in 57 clinical trials of anti-VEGF treatment, including bevacizumab, indicated that the rate of intracranial hemorrhage in high-grade glioma, and brain metastases,&#x000a0;is nominal.<xref ref-type="bibr" rid="article-18246.r31">[31]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Surgery and wound healing complications: Incidents of wound healing and surgical complications (including serious and fatal complications) increase in patients treated with bevacizumab. It should not be given for the 28 days before an elective surgical procedure, at least 28 days following surgery, or until complete healing of the surgical wounds.&#x000a0;Necrotizing fasciitis has been documented in patients receiving bevacizumab. Discontinue bevacizumab in patients who develop necrotizing fasciitis.<xref ref-type="bibr" rid="article-18246.r32">[32]</xref><xref ref-type="bibr" rid="article-18246.r33">[33]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Arterial thromboembolic events (ATE): The risk of cerebral infarction, transient ischemic attacks, myocardial infarction, and angina&#x000a0;is higher&#x000a0;in patients receiving&#x000a0;bevacizumab. In a postmarketing retrospective cohort study involving 2012 patients, acute coronary syndrome and stroke rates were higher two years after intravitreal bevacizumab.<xref ref-type="bibr" rid="article-18246.r34">[34]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Severe hypertension: Hypertension&#x000a0;occurs as anti-VEGF therapy causes&#x000a0;enhanced&#x000a0;expression of the pre-pro ET-1 gene, increasing endothelin-1 and decreasing NO bioavailability.&#x000a0;Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, and calcium channel blockers are all commonly used to treat&#x000a0;bevacizumab-induced hypertension. As NO availability is decreased in patients with VEGF inhibitors-induced hypertension, long-acting oral nitrates have been&#x000a0;used&#x000a0;for refractory hypertension.<xref ref-type="bibr" rid="article-18246.r35">[35]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Renal injury and proteinuria: As discussed above, nephrotic syndrome and proteinuria are potential complications of bevacizumab therapy. Nephrotic syndrome requires cessation of bevacizumab treatment, while proteinuria needs temporary discontinuation and monitoring.<xref ref-type="bibr" rid="article-18246.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>Posterior reversible encephalopathy syndrome (PRES):&#x000a0;PRES is a neurological complication characterized by headaches, seizures, visual disturbances, nausea &#x00026; vomiting associated with hypertension. Discontinuing bevacizumab and blood pressure control is recommended.<xref ref-type="bibr" rid="article-18246.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p>Ovarian failure:&#x000a0; &#x000a0;VEGFA is assumed to play an essential role in regulating angiogenesis in the ovary. The incidence of ovarian failure&#x000a0;increases in premenopausal women&#x000a0;given&#x000a0;bevacizumab. Bevacizumab induces ovarian damage; it is likely that this damage is temporary and disappears within the expected drug clearance in most cases. However, frequent and prolonged drug therapy may complicate the toxicity, and fertility may be temporarily or permanently&#x000a0;compromised&#x000a0;following bevacizumab administration.<xref ref-type="bibr" rid="article-18246.r37">[37]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Congestive heart failure:&#x000a0;Bevacizumab treatment significantly increases cancer patients' risk of developing CHF. In a meta-analysis, increased&#x000a0;risks of developing CHF were observed in patients with breast cancer, renal cell cancer, and glioblastoma. Asymptomatic LVEF dysfunction during bevacizumab therapy should be&#x000a0;treated with&#x000a0;ACE inhibitors. Discontinuation of bevacizumab is recommended in CHF.<xref ref-type="bibr" rid="article-18246.r38">[38]</xref><xref ref-type="bibr" rid="article-18246.r39">[39]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18246.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are currently no contraindications listed for bevacizumab.&#x000a0;Bevacizumab should not be administered in a dextrose solution due to the formation of insoluble aggregates.<xref ref-type="bibr" rid="article-18246.r40">[40]</xref></p>
      </sec>
      <sec id="article-18246.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitoring for signs of an infusion reaction is necessary during&#x000a0;infusions with bevacizumab. Additional monitoring includes CBC with differential, blood pressure monitoring every 2 to 3 weeks, and tracking for proteinuria. Patients also require monitoring for signs of GI perforation, epistaxis, and arterial and venous thromboembolism. When bevacizumab is used off-label for diabetic macular edema, clinicians should watch for intraocular pressure, visual acuity, and signs of cataracts and retinal detachment. Monitor for severe hemorrhage, wound healing complications, GI fistulae, non-GI fistulae, hypertension, and ovarian failure.<xref ref-type="bibr" rid="article-18246.r41">[41]</xref><bold>&#x000a0;</bold>The healthcare team should monitor for signs of fluid overload and heart failure.<xref ref-type="bibr" rid="article-18246.r39">[39]</xref></p>
      </sec>
      <sec id="article-18246.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Researchers have not yet conducted extensive mutagenicity&#x000a0;and carcinogenicity studies. Administration of bevacizumab in monkeys showed adverse effects on general growth and development, fertility, and wound healing. Teratogenicity is suspected based on studies in rabbits. There is no recommended treatment or antidote for an overdose of bevacizumab.<xref ref-type="bibr" rid="article-18246.r42">[42]</xref>&#x000a0;Infusion reactions can be severe, requiring discontinuation and early&#x000a0;therapy for hypersensitivity reactions requires prompt treatment.<xref ref-type="bibr" rid="article-18246.r43">[43]</xref></p>
      </sec>
      <sec id="article-18246.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Bevacizumab is usually only prescribed by&#x000a0;specific clinicians, including oncologists, rheumatologists, ophthalmologists, immunologists, and ophthalmologists. However, the routine monitoring of patients treated with bevacizumab is done by nurses. Monitoring for signs of an infusion reaction is necessary during&#x000a0;infusions with bevacizumab; this will largely be the responsibility of the nursing staff. Additional monitoring includes CBC with differential, blood pressure monitoring every 2 to 3 weeks, and monitoring for proteinuria. Additionally, patient education by healthcare providers should include risk-benefit evaluation and consideration of severe hypertension, gastrointestinal complications, bleeding tendencies, and arterial and venous thromboembolism.</p>
        <p>Warnings and precautions include GI perforation, bleeding, surgery, and wound healing complications. The pharmacist must educate the patient on the drug's potential benefits and toxicity. Pharmacists must also examine bevacizumab in the context of the patient's overall drug regimen and report any interactions or concerns to the treating physician. Challenging cases may require an oncology-certified pharmacy practitioner.&#x000a0;Communication between the clinicians, pharmacists, and nurses who prescribe, dispense and administer this agent is vital to prevent serious adverse effects.&#x000a0;Bevacizumab requires all interprofessional healthcare team members to collaborate and communicate to optimize therapy and minimize adverse reactions. [Level 5]</p>
        <p>In addition, a study examined the outcomes of ovarian cancer by patient-centered care through a multidisciplinary, interprofessional approach involving gynecological surgeons, pathologists, oncologists and collaboration with other healthcare professionals, including nurses, radiologists, nuclear medicine physicians, nutritionists, vascular surgeons, urologists, gynecologists, and&#x000a0;psychologists can provide valuable input&#x000a0;in all the decision-making steps of ovarian cancer management which translates to better patient outcomes.<xref ref-type="bibr" rid="article-18246.r44">[44]</xref>&#x000a0;[Level 5]</p>
      </sec>
      <sec id="article-18246.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18246&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18246">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18246/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18246">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18246.s11">
        <title>References</title>
        <ref id="article-18246.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kandasamy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Constantinou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Wickremasinghe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Al-Qureshi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>LL</given-names>
              </name>
            </person-group>
            <article-title>Prospective randomised clinical trial of intravitreal bevacizumab versus triamcinolone in eyes with diabetic macular oedema undergoing cataract surgery: 6-month results.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>103</volume>
            <issue>12</issue>
            <fpage>1753</fpage>
            <page-range>1753-1758</page-range>
            <pub-id pub-id-type="pmid">30819688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Belin</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Greaves</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kosoy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lieberman</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>The use of bevacizumab in pediatric retinal and choroidal disease: A review.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2019</year>
            <month>May</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>338</fpage>
            <page-range>338-347</page-range>
            <pub-id pub-id-type="pmid">30757919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhuang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues.</article-title>
            <source>Mol Cancer</source>
            <year>2019</year>
            <month>Feb</month>
            <day>07</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <pub-id pub-id-type="pmid">30732625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perdrizet</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Leighl</surname>
                <given-names>NB</given-names>
              </name>
            </person-group>
            <article-title>The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer.</article-title>
            <source>Curr Treat Options Oncol</source>
            <year>2019</year>
            <month>Feb</month>
            <day>18</day>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>21</fpage>
            <pub-id pub-id-type="pmid">30778772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marchetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Muzii</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Romito</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Benedetti Panici</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>First-line treatment of women with advanced ovarian cancer: focus on bevacizumab.</article-title>
            <source>Onco Targets Ther</source>
            <year>2019</year>
            <volume>12</volume>
            <fpage>1095</fpage>
            <page-range>1095-1103</page-range>
            <pub-id pub-id-type="pmid">30799939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finn</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Galle</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Ducreux</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Kudo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Breder</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Merle</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kaseb</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Verret</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>DZ</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mulla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>AX</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>AL</given-names>
              </name>
              <collab>IMbrave150 Investigators</collab>
            </person-group>
            <article-title>Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>May</month>
            <day>14</day>
            <volume>382</volume>
            <issue>20</issue>
            <fpage>1894</fpage>
            <page-range>1894-1905</page-range>
            <pub-id pub-id-type="pmid">32402160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hey</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Gyawali</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>D'Andrea</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kanagaraj</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kesselheim</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2020</year>
            <month>Apr</month>
            <day>01</day>
            <volume>112</volume>
            <issue>4</issue>
            <fpage>335</fpage>
            <page-range>335-342</page-range>
            <pub-id pub-id-type="pmid">31651981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Azzopardi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dupuis-Girod</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ternant</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fargeton</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Ginon</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Faure</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Decullier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Roux</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carette</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Gilbert-Dussardier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hatron</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Lacombe</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Leguy-Seguin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rivi&#x000e8;re</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Corre</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bailly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paintaud</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.</article-title>
            <source>MAbs</source>
            <year>2015</year>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>630</fpage>
            <page-range>630-7</page-range>
            <pub-id pub-id-type="pmid">25751241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montanino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Manzo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carillio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Palumbo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Esposito</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sforza</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Costanzo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sandomenico</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Botti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Piccirillo</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Cascetta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pascarella</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>La Manna</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Normanno</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Morabito</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Angiogenesis Inhibitors in Small Cell Lung Cancer.</article-title>
            <source>Front Oncol</source>
            <year>2021</year>
            <volume>11</volume>
            <fpage>655316</fpage>
            <pub-id pub-id-type="pmid">34123809</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hummel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bosje</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Barve</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kothekar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Socinski</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Waller</surname>
                <given-names>CF</given-names>
              </name>
            </person-group>
            <article-title>A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab.</article-title>
            <source>J Cancer Res Clin Oncol</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>148</volume>
            <issue>2</issue>
            <fpage>487</fpage>
            <page-range>487-496</page-range>
            <pub-id pub-id-type="pmid">33866430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Peyret</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Marchand</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Quartino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gosselin</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Girish</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Allison</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Population pharmacokinetics of bevacizumab in cancer patients with external validation.</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>78</volume>
            <issue>2</issue>
            <fpage>341</fpage>
            <page-range>341-51</page-range>
            <pub-id pub-id-type="pmid">27329360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gojo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sauermann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Knaack</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Slavc</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Peyrl</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3&#x000a0;Years with CNS Malignancies.</article-title>
            <source>Drugs R D</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>469</fpage>
            <page-range>469-474</page-range>
            <pub-id pub-id-type="pmid">28577293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <chapter-title>Bevacizumab (Antineoplastic)</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>9</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">31644184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glade Bender</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Adamson</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Baruchel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shaked</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kerbel</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Cooney-Qualter</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Stempak</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>HX</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Krailo</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Ingle</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Blaney</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Kandel</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Yamashiro</surname>
                <given-names>DJ</given-names>
              </name>
              <collab>Children's Oncology Group Study</collab>
            </person-group>
            <article-title>Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.</article-title>
            <source>J Clin Oncol</source>
            <year>2008</year>
            <month>Jan</month>
            <day>20</day>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>399</fpage>
            <page-range>399-405</page-range>
            <pub-id pub-id-type="pmid">18202416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taira</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Okazaki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Akiyoshi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Machida</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ikeya</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nakata</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nadatani</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ohminami</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fukunaga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Otani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hosomi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kamata</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nagami</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fujiwara</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Short bevacizumab infusion as an effective and safe treatment for colorectal cancer.</article-title>
            <source>Mol Clin Oncol</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>139</fpage>
            <pub-id pub-id-type="pmid">35949896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poku</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rathbone</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Everson-Hock</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Essat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pandor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wailoo</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review.</article-title>
            <source>BMJ Open</source>
            <year>2014</year>
            <month>Jul</month>
            <day>17</day>
            <volume>4</volume>
            <issue>7</issue>
            <fpage>e005244</fpage>
            <pub-id pub-id-type="pmid">25034629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khalid</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khalid</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Haddad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Spiro</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Daw</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Dosage Adjustments for Chemotherapy and Targeted Therapies in Colorectal and Pancreatic Cancer Patients with Hepatic Impairment.</article-title>
            <source>Cureus</source>
            <year>2018</year>
            <month>Jun</month>
            <day>13</day>
            <volume>10</volume>
            <issue>6</issue>
            <fpage>e2798</fpage>
            <pub-id pub-id-type="pmid">30116677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brandes</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Bartolotti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tosoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Poggi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Franceschi</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Practical management of bevacizumab-related toxicities in glioblastoma.</article-title>
            <source>Oncologist</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>166</fpage>
            <page-range>166-75</page-range>
            <pub-id pub-id-type="pmid">25568148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cross</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Ratner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rutherford</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Norwitz</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Bevacizumab-mediated interference with VEGF signaling is sufficient to induce a preeclampsia-like syndrome in nonpregnant women.</article-title>
            <source>Rev Obstet Gynecol</source>
            <year>2012</year>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-8</page-range>
            <pub-id pub-id-type="pmid">22582121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Korenaga</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Tewari</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Gynecologic cancer in pregnancy.</article-title>
            <source>Gynecol Oncol</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>157</volume>
            <issue>3</issue>
            <fpage>799</fpage>
            <page-range>799-809</page-range>
            <pub-id pub-id-type="pmid">32268951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Polizzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mahajan</surname>
                <given-names>VB</given-names>
              </name>
            </person-group>
            <article-title>Intravitreal Anti-VEGF Injections in Pregnancy: Case Series and Review of Literature.</article-title>
            <source>J Ocul Pharmacol Ther</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>31</volume>
            <issue>10</issue>
            <fpage>605</fpage>
            <page-range>605-10</page-range>
            <pub-id pub-id-type="pmid">26302032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r22">
          <label>22</label>
          <element-citation publication-type="book">
            <chapter-title>Bevacizumab</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>12</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Belgioia</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Desideri</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Errico</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Franzese</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Daidone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marino</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fiore</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Borghetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Greto</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fiorentino</surname>
                <given-names>A</given-names>
              </name>
              <collab>AIRO Giovani Italian Association of Radiation Oncology-Young Members Working Group</collab>
            </person-group>
            <article-title>Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: A literature review.</article-title>
            <source>Crit Rev Oncol Hematol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>133</volume>
            <fpage>163</fpage>
            <page-range>163-170</page-range>
            <pub-id pub-id-type="pmid">30661652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaveh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ebrahimi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rezapour</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mozafari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sayehmiri</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis.</article-title>
            <source>Int J Clin Pharm</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-41</page-range>
            <pub-id pub-id-type="pmid">30610548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burger</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Bookman</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Monk</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Homesley</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Greer</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Boente</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fleming</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Katsumata</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>SX</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.</article-title>
            <source>J Clin Oncol</source>
            <year>2014</year>
            <month>Apr</month>
            <day>20</day>
            <volume>32</volume>
            <issue>12</issue>
            <fpage>1210</fpage>
            <page-range>1210-7</page-range>
            <pub-id pub-id-type="pmid">24637999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Muramatsu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakajima</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Narayama</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Narayama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Goya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tsukada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Machida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kuramoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mikami</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Recurrent Cervical Cancer with Intestinal Perforation That Was Related to Bevacizumab after Long-term NSAIDs Administration and Was Treated with Laparoscopy-assisted Anastomosis.</article-title>
            <source>Tokai J Exp Clin Med</source>
            <year>2019</year>
            <month>Sep</month>
            <day>20</day>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>40</fpage>
            <page-range>40-44</page-range>
            <pub-id pub-id-type="pmid">31448394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hwang</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Shim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Son</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal/genitourinary perforation and fistula formation with or without bevacizumab in patients with previously irradiated recurrent cervical cancer: a Korean multicenter retrospective study of the Gynecologic Oncology Research Investigators Collaboration (GORILLA) group (GORILLA-1001).</article-title>
            <source>BMC Cancer</source>
            <year>2022</year>
            <month>Jun</month>
            <day>02</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>603</fpage>
            <pub-id pub-id-type="pmid">35655188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoshimoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yoshikawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Higashijima</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Miyatani</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tokunaga</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nishi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takasu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kashihara</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takehara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shimada</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Bevacizumab-associated intestinal perforation and perioperative complications in patients receiving bevacizumab.</article-title>
            <source>Ann Gastroenterol Surg</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>151</fpage>
            <page-range>151-155</page-range>
            <pub-id pub-id-type="pmid">32258980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishie</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yasuo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kitaguchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tateishi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ushiki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Urushihata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ideura</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hanaoka</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Bevacizumab-induced tracheoesophageal fistula in a patient suffering from lung cancer with bulky subcarinal lymph node: a case report.</article-title>
            <source>Nagoya J Med Sci</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>80</volume>
            <issue>1</issue>
            <fpage>129</fpage>
            <page-range>129-134</page-range>
            <pub-id pub-id-type="pmid">29581622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barlesi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Crin&#x000f2;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Henschke</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Isla</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stiebeler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Spigel</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts.</article-title>
            <source>Ann Oncol</source>
            <year>2012</year>
            <month>May</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>1111</fpage>
            <page-range>1111-1120</page-range>
            <pub-id pub-id-type="pmid">22056855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Daras</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pentsova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nolan</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Gavrilovic</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>DeAngelis</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Kaley</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Bevacizumab in high-grade glioma patients following intraparenchymal hemorrhage.</article-title>
            <source>Neurooncol Pract</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-28</page-range>
            <pub-id pub-id-type="pmid">31044081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sendur</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Aksoy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>&#x000d6;zdemir</surname>
                <given-names>NY</given-names>
              </name>
              <name>
                <surname>Zengin</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma.</article-title>
            <source>Indian J Pharmacol</source>
            <year>2014</year>
            <season>Jan-Feb</season>
            <volume>46</volume>
            <issue>1</issue>
            <fpage>125</fpage>
            <page-range>125-6</page-range>
            <pub-id pub-id-type="pmid">24550600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haider</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gurjar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ghazanfar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chilimuri</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Necrotizing Fasciitis In A Patient with Metastatic Clear Cell Ovarian Carcinoma Treated with Bevacizumab.</article-title>
            <source>Am J Case Rep</source>
            <year>2022</year>
            <month>Jun</month>
            <day>25</day>
            <volume>23</volume>
            <fpage>e935584</fpage>
            <pub-id pub-id-type="pmid">35751369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weinstein</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Abu Tailakh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lifshitz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Novack</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Intravitreal bevacizumab treatment for neovascular age-related macular degeneration and thromboembolic events.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <page-range>66-71</page-range>
            <pub-id pub-id-type="pmid">30618282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kroetz</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.</article-title>
            <source>Pharmacol Ther</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>182</volume>
            <fpage>152</fpage>
            <page-range>152-160</page-range>
            <pub-id pub-id-type="pmid">28882537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seet</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Rabinstein</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment.</article-title>
            <source>QJM</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>105</volume>
            <issue>1</issue>
            <fpage>69</fpage>
            <page-range>69-75</page-range>
            <pub-id pub-id-type="pmid">21865314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Imai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ichigo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matsunami</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takagi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kawabata</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Ovarian function following targeted anti-angiogenic therapy with bevacizumab.</article-title>
            <source>Mol Clin Oncol</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>807</fpage>
            <page-range>807-810</page-range>
            <pub-id pub-id-type="pmid">28588768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qi</surname>
                <given-names>WX</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>XM</given-names>
              </name>
            </person-group>
            <article-title>Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups.</article-title>
            <source>Clin Drug Investig</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>34</volume>
            <issue>10</issue>
            <fpage>681</fpage>
            <page-range>681-90</page-range>
            <pub-id pub-id-type="pmid">25096848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Economopoulou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kotsakis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kapiris</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kentepozidis</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Cancer therapy and cardiovascular risk: focus on bevacizumab.</article-title>
            <source>Cancer Manag Res</source>
            <year>2015</year>
            <volume>7</volume>
            <fpage>133</fpage>
            <page-range>133-43</page-range>
            <pub-id pub-id-type="pmid">26082660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Dextrose-mediated aggregation of therapeutic monoclonal antibodies in human plasma: Implication of isoelectric precipitation of complement proteins.</article-title>
            <source>MAbs</source>
            <year>2015</year>
            <volume>7</volume>
            <issue>6</issue>
            <fpage>1094</fpage>
            <page-range>1094-103</page-range>
            <pub-id pub-id-type="pmid">26338058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holekamp</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>Review of neovascular age-related macular degeneration treatment options.</article-title>
            <source>Am J Manag Care</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>10 Suppl</issue>
            <fpage>S172</fpage>
            <page-range>S172-S181</page-range>
            <pub-id pub-id-type="pmid">31419088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Avallone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giuliani</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>TRIBE2 results and toxicity.</article-title>
            <source>Lancet Oncol</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>e299</fpage>
            <pub-id pub-id-type="pmid">32502451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garc&#x000ed;a Gil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guti&#x000e9;rrez Nicol&#x000e1;s</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez De La Fuente</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Nazco Casariego</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Vi&#x000f1;a Romero</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Batista L&#x000f3;pez</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Ten-minute administration of bevacizumab.</article-title>
            <source>Eur J Hosp Pharm</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>218</fpage>
            <page-range>218-219</page-range>
            <pub-id pub-id-type="pmid">31338171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18246.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Falzone</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Scandurra</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lombardo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gattuso</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lavoro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Distefano</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Scibilia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Scollo</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review).</article-title>
            <source>Int J Oncol</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>59</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">34132354</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
